Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Tomasz Kloskowski is active.

Publication


Featured researches published by Tomasz Kloskowski.


International Journal of Biological Macromolecules | 2016

3D composites based on the blends of chitosan and collagen with the addition of hyaluronic acid

Alina Sionkowska; Beata Kaczmarek; Katarzyna Lewandowska; Sylwia Grabska; Marta Pokrywczyńska; Tomasz Kloskowski; Tomasz Drewa

3D porous composites based on blends of chitosan, collagen and hyaluronic acid were obtained through the lyophilization process. Mechanical properties, swelling behavior and thermal stability of the blends were studied. Moreover, SEM images were taken and the structure of the blends was studied. Biological properties of the materials obtained were investigated by analyzing of proliferation rate of fibroblast cells incubated with biomaterial extract using MTT assay (3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide). The results showed that the properties of 3D composites based on the blends of chitosan and collagen were altered after the addition 1%, 2% and 5% of hyaluronic acid. Mechanical properties and thermal stability of chitosan/collagen blends were improved in the presence of hyaluronic acid in the composite. New 3D materials based on the blends of chitosan, collagen and hyaluronic acid were non-toxic and did not significantly affect cell morphology.


International Journal of Artificial Organs | 2013

Tissue Engineering and Ureter Regeneration: Is it Possible?:

Tomasz Kloskowski; Tomasz Kowalczyk; Maciej Nowacki; Tomasz Drewa

Large ureter damages are difficult to reconstruct. Current techniques are complicated, difficult to perform, and often associated with failures. The ureter has never been regenerated thus far. Therefore the use of tissue engineering techniques for ureter reconstruction and regeneration seems to be a promising way to resolve these problems. For proper ureter regeneration the following problems must be considered: the physiological aspects of the tissue, the type and shape of the scaffold, the type of cells, and the specific environment (urine). This review presents tissue engineering achievements in the field of ureter regeneration focusing on the scaffold, the cells, and ureter healing.


Transplantation Proceedings | 2012

Urine Is a Highly Cytotoxic Agent: Does It Influence Stem Cell Therapies in Urology?

Jan Adamowicz; Tomasz Kloskowski; Jakub Tworkiewicz; Marta Pokrywczyńska; Tomasz Drewa

The state of art of stem cell therapies in urologic regenerative medicine is still under development. There are still many issues before advances in tissue engineering can be introduced for clinical application. The essential question is whether stem cells should be seeded on the urinary tract lumen side. The present experiment, using Real-Time Cell Analyzer (RTCA) DP (Dual Plate) of the xCellligence system (Roche Applied Science, Mannheim, Germany), allowed us to monitor cellular events in real time. In this study we examined the influence of urine on bone marrow-derived mesenchymal stem cells (MSC). Cells were exposed to medium mixed with urine (1:1), medium mix with PBS (Phosphate Buffered Saline) (1:1), only urine, and whole medium without cells as background. The cell number was significantly lower in all groups exposed on medium mixed with urine and urine alone. The results showed that urine is a highly cytotoxic agent whose role in urologic regenerative medicine is underestimated.


Aging Clinical and Experimental Research | 2013

Does aging of mesenchymal stem cells limit their potential application in clinical practice

Anna Bajek; Mateusz Czerwiński; Joanna Olkowska; Natalia Gurtowska; Tomasz Kloskowski; Tomasz Drewa

Mesenchymal stem cells (MSCs) are in the center of attention of many investigators due to easy isolation from many tissues. MSC capability to differentiate into many cell types makes them a starting point of many new therapies, especially in tissue engineering. However, understanding the process of MSC aging is crucial for selecting donors for cellular therapies, which is necessary for successful treatment. Cell changes can be divided into three major groups. Changes which affect their proliferate rate, differentiation capability and genome stability lead to decrease of their usefulness in new therapies. There are many tools that can be used to describe and measure some features of aging in MSCs but the essence of this process is still unclear. The aim of this review is to take a deep look into the influence of donor age and in vitro aging on MSC properties.


International Journal of Oncology | 2012

Ciprofloxacin is a potential topoisomerase II inhibitor for the treatment of NSCLC.

Tomasz Kloskowski; Natalia Gurtowska; Joanna Olkowska; Jakub Marcin Nowak; Jan Adamowicz; Jakub Tworkiewicz; Robert Dębski; Alina Grzanka; Tomasz Drewa

Lung cancer is one of the most common tumors and its treatment is still inefficient. In our previous work we proved that ciprofloxacin has a different influence on five cancer cell lines. Here, we aimed to compare the biological effect of ciprofloxacin on cell lines representing different responses after treatment, thus A549 was chosen as a sensitive model, C6 and B16 as highly resistant. Three different cell lines were analyzed (A549, B16 and C6). The characterization of continuous cell growth was analyzed with the Real-Time Cell Analyzer (RTCA)-DP system. Cytoskeletal changes were demonstrated using immunofluorescence. The cell cycle was analyzed using flow cytometry. Ciprofloxacin was cytostatic only against the A549 cell line. In the case of other tested cell lines a cytostatic effect was not observed. Cytoskeletal analysis confirms the results obtained with RTCA-DP. A549 cells were inhibited in the G2/M phase suggesting a mechanism related to topoisomerase II inhibition. The biological effects of ciprofloxacin support the hypothesis that this drug can serve as an adjuvant treatment for lung cancer, due to its properties enabling topoisomerase II inhibition.


Pulmonary Pharmacology & Therapeutics | 2010

Does ciprofloxacin have an obverse and a reverse

Tomasz Kloskowski; Natalia Gurtowska; Tomasz Drewa

Ciprofloxacin is an antibiotic that belongs to fluoroquinoles, characterized by broad spectrum of action against pathogens, especially Gram(-) aerobic bacilli. For a long time, it has been thought that ciprofloxacin has an effect only on bacterial cells. Now it is known, that this drug can significantly affect eukaryotic cells including human cancer cells. Its bactericidal action relay on inhibition of topoisomerase II, enzyme responsible for alterations in 3D structure of DNA during replication, transcription and chromatin condensation. Thanks to that, ciprofloxacin can induce cell cycle arrest and apoptosis of cancer cells. The effectiveness of ciprofloxacin was confirmed in several in vitro studies on tumor cell lines such as: human bladder cells, leukaemic cell lines, human osteosarcoma cells, human prostate cancer cells, human colorectal carcinoma cells and human non-small cell lung cancer cell line. Ciprofloxacin is particularly effective against non-small cell lung cancer mainly due to accumulation of ciprofloxacin in lung tissue after intravenous administration and its toxicity against lung cancer lines in vitro in a concentration and time-dependent manner.


PLOS ONE | 2014

Ureter regeneration-the proper scaffold has to be defined.

Tomasz Kloskowski; Arkadiusz Jundziłł; Tomasz Kowalczyk; Maciej Nowacki; Magdalena Bodnar; Andrzej Marszałek; Marta Pokrywczyńska; Małgorzata Frontczak-Baniewicz; Tomasz Kowalewski; Piotr Chlosta; Tomasz Drewa

The aim of this study was to compare two different acellular scaffolds: natural and synthetic, for urinary conduit construction and ureter segment reconstruction. Acellular aortic arch (AAM) and poly(L-lactide-co-caprolactone) (PLCL) were used in 24 rats for ureter reconstruction in both tested groups. Follow-up period was 4 weeks. Intravenous pyelography, histological and immunohistochemical analysis were performed. All animals survived surgical procedures. Patent uretero-conduit junction was observed only in one case using PLCL. In case of ureter segment reconstruction ureters were patent in one case using AAM and in four cases using PLCL scaffolds. Regeneration of urothelium layer and focal regeneration of smooth muscle layer was observed on both tested scaffolds. Obtained results indicates that synthetic acellular PLCL scaffolds showed better properties for ureter reconstruction than naturally derived acellular aortic arch.


Journal of Cancer | 2016

Is mTOR inhibitor good enough for treatment all tumors in TSC patients

Samy L. Habib; Noor Y. Al-Obaidi; Maciej Nowacki; Katarzyna Pietkun; Barbara Zegarska; Tomasz Kloskowski; Wojciech Zegarski; Tomasz Drewa; Edward A. Medina; Zhenze Zhao; Sitai Liang

Tuberous sclerosis complex (TSC) is an autosomal dominant and multi-system genetic disorder in humans. TSC affects around 25,000 to 40,000 individuals in the United States and about 1 to 2 million individuals worldwide, with an estimated prevalence of one in 6,000 newborns. TSC occurs in all races and ethnic groups, and in both genders. TSC is caused by defects or mutations in two genes, TSC1 and TSC2. Loss of TSC1/TSC2 leads to dysregulation of mTOR, resulting in aberrant cell differentiation and development, and abnormal enlargement of cells. TSC is characterized by the development of benign and/or malignant tumors in several organs including renal/liver angiomyolipomas, facial angiofibroma, lymphangiomyomatosis, cardiac rhabdomyomas, retinal astrocytic, renal cell carcinoma, and brain subependymal giant cell astrocytomas (SEGA). In addition, TSC disease causes disabling neurologic disorders, including epilepsy, mental retardation and autism. Particularly problematic are the development of renal angiomyolipomas, which tend to be larger, bilateral, multifocal and present at a younger age compared with sporadic forms. In addition, SEGA block the flow of fluid within the brain, causing a buildup of fluid and pressure that leads to blurred vision and seizures. In the current review, we describe the pathology of TSC disease in key organs and summarize the use of mTOR inhibitors to treat tumors in TSC patients.


Aesthetic Surgery Journal | 2014

Filling Effects, Persistence, and Safety of Dermal Fillers Formulated With Stem Cells in an Animal Model

Maciej Nowacki; Katarzyna Pietkun; Marta Pokrywczyńska; Marta Rasmus; Karolina Warda; Tomasz Kloskowski; Arkadiusz Jundziłł; Maciej Gagat; Alina Grzanka; Magdalena Bodnar; Andrzej Marszałek; Tomasz Drewa; Rafał Czajkowski

BACKGROUND Research is scarce regarding the effectiveness of dermal fillers containing autologous stem cells. OBJECTIVES The authors sought to determine the local and systemic effects of adipose-derived stem cells (ADSCs) as a component of dermal fillers in an animal model. METHODS Wistar rats were injected with 1 of the following dermal fillers: ADSCs combined with hyaluronic acid (ADSC-HA), ADSCs combined with fish collagen (ADSC-COL), HA alone (CONTROL-HA), or COL alone (CONTROL-COL). Fillers were injected into the glabella, dorsum, and chest of each animal. The ADSCs were labeled with PKH26 to assess cell migration. Filling effects (FEs) were measured immediately after injection and at 1.5 months and 3 months after injection. Skin specimens were stained with hematoxylin and eosin to assess localization and persistence of ADSCs. RESULTS Mean FEs in animals implanted with ADSCs were greater and persisted longer than those of controls. No inflammatory responses were observed in any group. Three months after injection, PKH26-positive cells comprised nearly 70% of cells at the injection site in animals treated with ADSC-HA. PKH26 fluorescence also was detected in the spleen but not in the brain, kidney, or lung. CONCLUSIONS Stem cells have the potential to improve the aesthetic effects and longevity of dermal fillers.


Pancreas | 2014

Impact of fructose diet and renal failure on the function of pancreatic islets.

Marta Pokrywczyńska; Mariusz Flisiński; Arkadiusz Jundziłł; Sandra Krzyzanowska; Andrzej Brymora; Aleksander Deptuła; Magdalena Bodnar; Tomasz Kloskowski; Anna Stefańska; Andrzej Marszałek; Jacek Manitius; Tomasz Drewa

Objectives This study was designed to evaluate the impact of fructose-rich diet and chronic kidney disease (CKD) on the in vitro function of pancreatic islets. Methods Fifty-four rats were divided into 3 equal groups as follows: control, rats with CKD 1/2 that underwent surgical uninephrectomy, and rats with CKD 5/6 that underwent uninephrectomy and kidney cortex mass resection. Each group was further assigned to 3 diet protocols—regular diet, regular diet with 10% fructose (F10), and 60% fructose-rich diet (F60). After 8 weeks of insulin administration, C-peptide, glycated hemoglobin level, serum urea nitrogen, creatinine clearance, and homeostasis model assessment of insulin resistance were evaluated. Static glucose insulin stimulation test of isolated pancreatic islets and histologic analysis of pancreatic tissue were performed. Results The F10 diet increased the levels of insulin and C-peptide in all groups. Homeostasis model assessment of insulin resistance was increased in all animals fed with fructose. The elevated levels of creatinine and diminished creatinine clearance were detected in CKD 5/6 rats fed with 60% fructose-rich diet. The F10 diet resulted in high levels of serum insulin and C-peptide and glucose-stimulated insulin secretion. Fructose-rich diet increased the islet size and number, with irregular morphology and exocrine tissue fibrosis. Conclusions The fructose-rich diet accelerates the progression of CKD and affects the pancreatic islet function.

Collaboration


Dive into the Tomasz Kloskowski's collaboration.

Top Co-Authors

Avatar

Tomasz Drewa

Nicolaus Copernicus University in Toruń

View shared research outputs
Top Co-Authors

Avatar

Marta Pokrywczyńska

Nicolaus Copernicus University in Toruń

View shared research outputs
Top Co-Authors

Avatar

Maciej Nowacki

Nicolaus Copernicus University in Toruń

View shared research outputs
Top Co-Authors

Avatar

Arkadiusz Jundziłł

Nicolaus Copernicus University in Toruń

View shared research outputs
Top Co-Authors

Avatar

Andrzej Marszałek

Poznan University of Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Katarzyna Pietkun

Nicolaus Copernicus University in Toruń

View shared research outputs
Top Co-Authors

Avatar

Magdalena Bodnar

Nicolaus Copernicus University in Toruń

View shared research outputs
Top Co-Authors

Avatar

Anna Bajek

Nicolaus Copernicus University in Toruń

View shared research outputs
Top Co-Authors

Avatar

Natalia Gurtowska

Nicolaus Copernicus University in Toruń

View shared research outputs
Top Co-Authors

Avatar

Joanna Olkowska

Nicolaus Copernicus University in Toruń

View shared research outputs
Researchain Logo
Decentralizing Knowledge